Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Intern Med ; 56(10): 1179-1184, 2017.
Article in English | MEDLINE | ID: mdl-28502933

ABSTRACT

Leptospirosis is frequently associated with acute kidney injury. Some survivors are known to progress to chronic kidney disease due to sustained tubulointerstitial inflammation. We present a case of severe leptospirosis with acute renal failure. Although antibiotic therapy resolved the infection, moderate renal dysfunction remained. A renal biopsy demonstrated marked inflammatory infiltration in the tubules and interstitium. Many of the inflammatory cells were CD68-positive monocytes/macrophages, predominantly M1 phenotype. An intermediate dose of oral corticosteroids normalized the patient's serum creatinine levels. We suggest that corticosteroid therapy may be a therapeutic option for some patients with sustained tubulointerstitial nephritis who survive severe leptospirosis.


Subject(s)
Acute Kidney Injury/complications , Leptospirosis/complications , Nephritis, Interstitial/complications , Acute Kidney Injury/drug therapy , Acute Kidney Injury/pathology , Adrenal Cortex Hormones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Creatinine/blood , Humans , Leptospirosis/drug therapy , Leptospirosis/pathology , Male , Middle Aged , Nephritis, Interstitial/drug therapy , Nephritis, Interstitial/pathology
3.
PLoS One ; 9(6): e100777, 2014.
Article in English | MEDLINE | ID: mdl-24960177

ABSTRACT

Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2 inhibitors on the kidney is unknown. In addition, whether SGLT2 inhibitors have an anti-inflammatory or antioxidative stress effect is still unclear. In this study, to resolve these issues, we evaluated the effects of the SGLT2 inhibitor, dapagliflozin, using a mouse model of type 2 diabetes and cultured proximal tubular epithelial (mProx24) cells. Male db/db mice were administered 0.1 or 1.0 mg/kg of dapagliflozin for 12 weeks. Body weight, blood pressure, blood glucose, hemoglobin A1c, albuminuria and creatinine clearance were measured. Mesangial matrix accumulation and interstitial fibrosis in the kidney and pancreatic ß-cell mass were evaluated by histological analysis. Furthermore, gene expression of inflammatory mediators, such as osteopontin, monocyte chemoattractant protein-1 and transforming growth factor-ß, was evaluated by quantitative reverse transcriptase-PCR. In addition, oxidative stress was evaluated by dihydroethidium and NADPH oxidase 4 staining. Administration of 0.1 or 1.0 mg/kg of dapagliflozin ameliorated hyperglycemia, ß-cell damage and albuminuria in db/db mice. Serum creatinine, creatinine clearance and blood pressure were not affected by administration of dapagliflozin, but glomerular mesangial expansion and interstitial fibrosis were suppressed in a dose-dependent manner. Dapagliflozin treatment markedly decreased macrophage infiltration and the gene expression of inflammation and oxidative stress in the kidney of db/db mice. Moreover, dapagliflozin suppressed the high-glucose-induced gene expression of inflammatory cytokines and oxidative stress in cultured mProx24 cells. These data suggest that dapagliflozin ameliorates diabetic nephropathy by improving hyperglycemia along with inhibiting inflammation and oxidative stress.


Subject(s)
Benzhydryl Compounds/pharmacology , Diabetic Nephropathies/metabolism , Glucose/metabolism , Glucosides/pharmacology , Homeostasis/drug effects , Sodium-Glucose Transporter 2 Inhibitors , Animals , Apoptosis , Blood Glucose/drug effects , Body Weight/drug effects , Cells, Cultured , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/genetics , Diabetic Nephropathies/pathology , Disease Models, Animal , Gene Expression , Glomerular Mesangium/drug effects , Glomerular Mesangium/metabolism , Glomerular Mesangium/pathology , Inflammation/genetics , Inflammation/metabolism , Inflammation/pathology , Insulin-Secreting Cells/drug effects , Kidney/drug effects , Kidney/metabolism , Kidney/physiopathology , Kidney Cortex/metabolism , Kidney Cortex/pathology , Kidney Function Tests , Kidney Tubules, Proximal/metabolism , Kidney Tubules, Proximal/pathology , Macrophages/metabolism , Macrophages/pathology , Male , Mice , Oxidative Stress
4.
PLoS One ; 9(1): e85594, 2014.
Article in English | MEDLINE | ID: mdl-24465611

ABSTRACT

Nuclear hormone receptors (NHRs) are transcription factors that regulate carbohydrate and lipid metabolism, immune responses, and inflammation. Although several NHRs, including peroxisome proliferator-activated receptor-γ (PPARγ) and PPARα, demonstrate a renoprotective effect in the context of diabetic nephropathy (DN), the expression and role of other NHRs in the kidney are still unrecognized. To investigate potential roles of NHRs in the biology of the kidney, we used quantitative real-time polymerase chain reaction to profile the expression of all 49 members of the mouse NHR superfamily in mouse kidney tissue (C57BL/6 and db/m), and cell lines of mesangial (MES13), podocyte (MPC), proximal tubular epithelial (mProx24) and collecting duct (mIMCD3) origins in both normal and high-glucose conditions. In C57BL/6 mouse kidney cells, hepatocyte nuclear factor 4α, chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) and COUP-TFIII were highly expressed. During hyperglycemia, the expression of the NHR 4A subgroup including neuron-derived clone 77 (Nur77), nuclear receptor-related factor 1, and neuron-derived orphan receptor 1 significantly increased in diabetic C57BL/6 and db/db mice. In renal cell lines, PPARδ was highly expressed in mesangial and proximal tubular epithelial cells, while COUP-TFs were highly expressed in podocytes, proximal tubular epithelial cells, and collecting duct cells. High-glucose conditions increased the expression of Nur77 in mesangial and collecting duct cells, and liver x receptor α in podocytes. These data demonstrate NHR expression in mouse kidney cells and cultured renal cell lines and suggest potential therapeutic targets in the kidney for the treatment of DN.


Subject(s)
Diabetic Nephropathies/genetics , Gene Expression , Kidney/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Animals , COUP Transcription Factor II/genetics , COUP Transcription Factor II/metabolism , COUP Transcription Factors/genetics , COUP Transcription Factors/metabolism , Cell Line , Cells, Cultured , Diabetic Nephropathies/metabolism , Kidney/cytology , Kidney Tubules/cytology , Kidney Tubules/metabolism , Male , Mesangial Cells/metabolism , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Microscopy, Fluorescence , Nuclear Receptor Subfamily 4, Group A, Member 1/genetics , Nuclear Receptor Subfamily 4, Group A, Member 1/metabolism , Podocytes/metabolism , Receptors, Cytoplasmic and Nuclear/classification , Receptors, Cytoplasmic and Nuclear/metabolism , Repressor Proteins , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...